Acute Repetitive Seizures Market Overview

Acute Repetitive Seizures Sector: Growth Drivers and Challenges

Growth Drivers

Increased awareness and early diagnosis: Increased awareness drives the establishment and expansion of specialized epilepsy and neurology clinics. These centers focus on diagnosing and treating seizure disorders, leading to increased acute repetitive seizures market opportunities for products and services related to acute repetitive seizures. Campaigns such as the Global Campaign Against Epilepsy (GCAE) and initiatives by organizations such as the Epilepsy Foundation increase public awareness about seizures, leading to people seeking medical advice and early diagnosis.

Early diagnosis can significantly improve patient outcomes by initiating treatment before seizures get severe or frequent. This, in turn, leads to a higher demand for medications and therapies tailored to acute repetitive seizures.
Growing venture investments in neurological research: Venture capital provides the necessary companies to develop and commercialize new treatments for ARS. This includes research into novel pharmaceuticals, medical devices, and digital health solutions. Moreover, venture capital investments often support the extensive clinical trials needed to bring new ARS treatment to acute repetitive seizures market. This accelerates the development timeline and enhances the likelihood of successful product launches. For instance, U.S. venture investments are crucial in advancing the field of neurology and expanding the acute repetitive seizures market by supporting innovation, enhancing technology, and accelerating the development of new therapies. In 2023, venture investments in neurology companies in the U.S. totaled USD 1.2 billion.
Rising healthcare expenditure: Increased expenditure often results in better patient support programs, educational initiatives, and resources to help manage and understand acute repetitive seizures. This leads to better patient outcomes and adherence to treatment. For instance, according to the World Bank Group, the global health expenditure was 10.87% in 2020 as compared to 9.81 in 2019.

Moreover, rising healthcare spending can lead to more comprehensive insurance plans that cover a broader range of treatments and services for acute repetitive seizures. Insurance plans that cover consultations with neurologists or access to epilepsy centers support the use of comprehensive care models.

Challenges

Patient adherence: Poor adherence to prescribed therapies can lead to suboptimal treatment outcomes, affecting the perceived efficacy of medications and potentially limiting market growth. Non-adherence often results in more frequent seizures, which can increase emergency visits, hospitalizations, and overall healthcare costs, impacting the overall acute repetitive seizures market dynamics.
Regulatory challenges: Regulatory approval for new treatments can be time-consuming, involving extensive clinical trials and data requirements. Regulatory bodies impose rigorous standards for demonstrating the safety and efficacy of new treatments. Moreover, regulatory authorities often require extensive post-marketing surveillance to monitor long-term safety and effectiveness, which can add additional costs and regulatory challenges

Acute Repetitive Seizures Market: Key Insights

Base Year	2024
Forecast Year	2025-2037
CAGR	15.2%
Base Year Market Size (2024)	USD 3.84 billion
Forecast Year Market Size (2037)	USD 13.81 billion
Regional Scope	North America (U.S., and Canada) Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific) Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Latin America (Mexico, Argentina, Brazil, Rest of Latin America) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Acute Repetitive Seizures Segmentation

Product Type (NRL-1, USL-261, AZ-002, and Diastat Rectal Gel)

The USL-261 segment is estimated to dominate the acute repetitive seizures market with a significant CAGR during the forecast period. The FDA-approved USL-261 (instranasal midazolam) is a rescue therapy for acute treatment of intermittent, stereotypic episodes of frequent seizure activity. It can be used to treat seizure clusters, bouts of increased seizures, or acute repetitive seizures. The drug has become an effective and promising alternative to conventional routes. For instance, according to a 2023 study published by the National Library of Medicine stated that more than 50% of patients responded to the first dose of midazolam and did not experience another seizure with 24 hours after the first. Moreover, no serious adverse events were reported by the patients, making midazolam a relatively safe and well-tolerated option.

USI-261 offers a unique approach or mechanism of action compared to existing treatments, which provide more effective or targeted relief for ARS. By addressing specific unmet needs or offering advantages over existing therapies, USI-261 can differentiate itself in the competitive acute repetitive seizures market, potentially capturing a significant segment.

Our in-depth analysis of the acute repetitive seizures market includes the following segments

Product Type

NRL-1
USL-261
AZ-002
Diastat Rectal Gel

Acute Repetitive Seizures Industry - Regional Synopsis

North America Market Analysis

North America in acute repetitive seizures market is projected to dominate around 44.8% revenue share by the end of 2037. The region has a significant population with neurological disorders such as epilepsy, leading to substantial demand for ARS treatments. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2021, around 2.9 million U.S. adults reported having active epilepsy. The growing awareness and better diagnostic capabilities contribute to an increased patient pool. Both the U.S. and Canada have well-developed healthcare systems with extensive access to medical care and treatments. Insurance coverage and reimbursement policies impact the adoption and acute repetitive seizures market growth of new ARS therapies.

In the U.S. significant investment in research and development by pharmaceutical companies and biotech firms leads to continuous innovation in ARS treatments. Advances in drug formulation, targeted therapies, and novel mechanisms of action contribute to market growth. Moreover, engagement with healthcare providers and patient advocacy groups can facilitate adoption and integration of new treatments into standard care practices. The Epilepsy Innovation Institute (EI2), a research program managed by Epilepsy Foundation of America (EFA) fosters new approaches for the diagnosis and treatment of epilepsy and explores bold new ideas and combines novel expertise and technologies from other fields of science

APAC Market Statistics

Asia Pacific acute repetitive seizures market is expected to expand with a notable share by the end of 2037 owing to the increasing diagnosis rates and advancements in treatment options. The diverse healthcare systems impact the availability and adoption of treatments. Countries with more developed healthcare systems, such as Japan and Australia, offer comprehensive, universal healthcare systems that ensure access to essential medical services. This contributes to overall high health outcomes and quality of life for their residents.

In China, the National Medical Products Administration (NMPA) oversees drug approvals. The streamlining of the drug approval process and increased efficiency in regulatory procedures facilitate quicker market entry for new treatments. For instance, in 2024, China NMPA has approved the oral suspension of ganaxolone by Marinus Pharmaceuticals to treat epileptic seizures in patients two years of age and older with CDKL5 deficient disorder (CDD).

In India, NLM estimates about 10 million persons with epilepsy, with a significant proportion experiencing acute repetitive seizures. This high prevalence drives demand for effective treatments and management solutions. Moreover, government initiatives such as the National Program for Prevention and Control of cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) include components for neurological disorders, including epilepsy.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Acute Repetitive Seizures Landscape

Companies are developing novel antiepileptic drugs (AEDs) and innovative therapies specially targeting acute repetitive seizures. This includes creating medications with better efficacy, fewer side effects, and improved patient compliance. Moreover, significant investment in research and development helps in discovering new treatment options and understanding seizure mechanisms. Collaborations with other pharmaceutical companies and biotech firms help in co-developing new treatments and sharing technological expertise.

Some of the major key players in acute repetitive seizures market include:

UCB S.A., Belgium
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Neurelis, Inc.
Bausch Health Companies Inc.
Alexza Pharmaceuticals, Inc.
Veriton Pharma
Pfizer Inc.
Sanofi S.A.
Novartis Pharma AG
Neos Therapeutics, Inc.
Sage Therapeutics, Inc.

In the News

In January 2020, Neurelis, Inc. announced that VALTOCO (diazepam nasal spray) has been approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of episodic, stereotypic episodes of frequent seizure activity (such as acute repetitive seizures, seizure clusters), in individuals with epilepsy aged 6 years and older, that differ from the patient's typical seizure pattern. Intravail is a component of VALTOCO's special formulation, which ensures dependable and constant absorption.
In May 2019, UCB S.A., Belgium announced today that the FDA has accepted a New Drug Application for NAYZILAM (midazolam) nasal spray CIV, the company's newest anti-epileptic drug (AED). This benzodiazepine is indicated for the acute treatment of episodic, stereotypic episodes of frequent seizure activity (i.e., acute repetitive seizures, seizure clusters), which are different from a patient's typical seizure pattern in patients with epilepsy 12 years of age and older. Patients and caregivers now have access to the first and only FDA-approved nasal treatment for seizure clusters with the advent of NAYZILAM.

Acute Repetitive Seizures Market Size & Share, by Product Type (NRL-1, USL-261, AZ-002, and Diastat Rectal Gel) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Global Market Size, Forecast, and Trend Highlights Over 2025-2037